Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: Royalty Pharma plc, 3 years.
Royalty Pharma plc
Director
Structure Therapeutics Inc.
Director
Gilead Sciences Inc.
Director
Jazz Pharmaceuticals plc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Structure Therapeutics Inc. June 17, 202699.7%
-
Royalty Pharma plc June 4, 202695.3%
-
Gilead Sciences Inc. April 30, 202698.3%
-
Royalty Pharma plc May 12, 202592.9%
-
Gilead Sciences Inc. May 7, 202598.4%
-
Royalty Pharma plc June 6, 202494.1%
-
Gilead Sciences Inc. May 8, 202499.5%
-
Royalty Pharma plc June 22, 202398.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 31, 2026 | Jazz Pharmaceuticals plc | Shares withheld for tax | −6 | $244.06 | $1,464 |
| Aug 31, 2026 | Jazz Pharmaceuticals plc | Shares withheld for tax | −737 | $241.39 | $177,904 |
| Aug 5, 2026 | Jazz Pharmaceuticals plc | Grant or award | +1,605 | — | — |
| Jun 5, 2026 | Royalty Pharma plc | Grant or award | +4,545 | — | — |
| Apr 30, 2026 | Gilead Sciences Inc. | Grant or award | +1,146 | — | — |
| Feb 26, 2026 | Jazz Pharmaceuticals plc | Grant or award | +1,527 | — | — |
| May 13, 2025 | Royalty Pharma plc | Grant or award | +7,614 | — | — |
| May 7, 2025 | Gilead Sciences Inc. | Grant or award | +1,516 | — | — |
| Jun 7, 2024 | Royalty Pharma plc | Grant or award | +9,293 | — | — |
| May 8, 2024 | Gilead Sciences Inc. | Grant or award | +2,310 | — | — |
| Feb 2, 2024 | Gilead Sciences Inc. | Grant or award | +512 | — | — |
| Jun 23, 2023 | Royalty Pharma plc | Grant or award | +7,747 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.